Company profile IGMS

IGM Biosciences Inc
igm biosciences, inc., a biotechnology company, engages in the research and development of immunoglobulin m (igm) antibodies for the treatment of cancer. the company's lead product candidate is igm-2323, a bispecific igm antibody that is in phase 1 clinical trials to treat patients with b cell nhl and other b cell malignancies. it is also developing igm-8444, an igm antibody ta...rgeting death receptor 5 proteins; and igm-7354, is a bispecific igm antibody delivering interleukin-15 cytokines to pd-l1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. igm biosciences, inc. has a collaboration with atreca inc. and beigene ltd. to discover, develop, and manufacture novel igm and iga antibodies targeting sars-cov-2 for the potential treatment of covid-19; and strategic research collaboration and license agreement with abcellera to discover and develop igm antibodies. the company was formerly known as palingen, inc. and changed its name to igm biosci Show More
Quarter analysis & expected interestLast update: November 06 2023 02:18:39.

After 34 days of this quarter the interest is at 126.0. Based on that we can calculate that during remaining 58 days it will total up to 341.0.
IGM Biosciences stock expected interest is significantly higher compared to previous quarter (+136.8%) and same quarter last year (+693.0%).

YearQ1Q2Q3Q4
2018 - - - 58
2019 94
62.1% QoQ
199
111.7% QoQ
112
-43.7% QoQ
69
19.0% YoY -38.4% QoQ
2020 133
41.5% YoY 92.8% QoQ
45
-77.4% YoY -66.2% QoQ
117
4.5% YoY 160.0% QoQ
142
105.8% YoY 21.4% QoQ
2021 238
78.9% YoY 67.6% QoQ
72
60.0% YoY -69.7% QoQ
77
-34.2% YoY 6.9% QoQ
189
33.1% YoY 145.5% QoQ
2022 182
-23.5% YoY -3.7% QoQ
211
193.1% YoY 15.9% QoQ
190
146.8% YoY -10.0% QoQ
43
-77.2% YoY -77.4% QoQ
2023 60
-67.0% YoY 39.5% QoQ
162
-23.2% YoY 170.0% QoQ
144
-24.2% YoY -11.1% QoQ
126
193.0% YoY -12.5% QoQ
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and IGM Biosciences stock search interestLast update: November 06 2023 02:18:38.
Correlation coefficient between keyword and revenue is -0.49
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: November 06 2023 02:18:39.

The average 5 years interest of IGM Biosciences stock was 10.24 per week.
The last year interest of IGM Biosciences stock compared to the last 5 years has changed by -7.62%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by -7.53%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 03:15:36.

After 39 days of this quarter the interest is at 31.0. Based on that we can calculate that during remaining 52 days it will total up to 72.0.
IGM Biosciences news expected interest is significantly higher compared to previous quarter (+75.6%) but similar to same quarter last year.

YearQ1Q2Q3Q4
201990
246
173.3% QoQ
67
-72.8% QoQ
37
-44.8% QoQ
2020 81
-10.0% YoY 118.9% QoQ
47
-80.9% YoY -42.0% QoQ
59
-11.9% YoY 25.5% QoQ
100
170.3% YoY 69.5% QoQ
2021 55
-32.1% YoY -45.0% QoQ
224
376.6% YoY 307.3% QoQ
22
-62.7% YoY -90.2% QoQ
68
-32.0% YoY 209.1% QoQ
2022 25
-54.5% YoY -63.2% QoQ
133
-40.6% YoY 432.0% QoQ
154
600.0% YoY 15.8% QoQ
99
45.6% YoY -35.7% QoQ
2023 86
244.0% YoY -13.1% QoQ
146
9.8% YoY 69.8% QoQ
89
-42.2% YoY -39.0% QoQ
41
-58.6% YoY -53.9% QoQ
2024 31
-64.0% YoY -24.4% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and IGM Biosciences news search interestLast update: February 09 2024 03:15:35.
Correlation coefficient between keyword and revenue is -0.57
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 03:15:39.

The average 5 years interest of IGM Biosciences news was 7.28 per week.
The last year interest of IGM Biosciences news compared to the last 5 years has changed by -18.96%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -30.26%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for IGM Biosciences immunoglobulin M antibodies to provide analysis

Correlation between past revenue and IGM Biosciences immunoglobulin M antibodies search interest

There is not enough data for IGM Biosciences immunoglobulin M antibodies to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IGM Biosciences immunoglobulin M antibodies to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for IGM Biosciences clinical-stage biotechnology to provide analysis

Correlation between past revenue and IGM Biosciences clinical-stage biotechnology search interest

There is not enough data for IGM Biosciences clinical-stage biotechnology to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IGM Biosciences clinical-stage biotechnology to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for IGM Biosciences CD20 x CD3 bispecific antibody to provide analysis

Correlation between past revenue and IGM Biosciences CD20 x CD3 bispecific antibody search interest

There is not enough data for IGM Biosciences CD20 x CD3 bispecific antibody to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IGM Biosciences CD20 x CD3 bispecific antibody to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for IGM Biosciences Phase 2 clinical trials to provide analysis

Correlation between past revenue and IGM Biosciences Phase 2 clinical trials search interest

There is not enough data for IGM Biosciences Phase 2 clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IGM Biosciences Phase 2 clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for IGM Biosciences B cell non-Hodgkin's lymphoma to provide analysis

Correlation between past revenue and IGM Biosciences B cell non-Hodgkin's lymphoma search interest

There is not enough data for IGM Biosciences B cell non-Hodgkin's lymphoma to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IGM Biosciences B cell non-Hodgkin's lymphoma to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for IGM Biosciences solid cancers to provide analysis

Correlation between past revenue and IGM Biosciences solid cancers search interest

There is not enough data for IGM Biosciences solid cancers to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IGM Biosciences solid cancers to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for IGM Biosciences anti-PD-L1 antibody to provide analysis

Correlation between past revenue and IGM Biosciences anti-PD-L1 antibody search interest

There is not enough data for IGM Biosciences anti-PD-L1 antibody to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IGM Biosciences anti-PD-L1 antibody to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for IGM Biosciences multiple myeloma to provide analysis

Correlation between past revenue and IGM Biosciences multiple myeloma search interest

There is not enough data for IGM Biosciences multiple myeloma to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IGM Biosciences multiple myeloma to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for IGMS
Earnings date: 2024-03-28 After close
Company name: IGM Biosciences Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2025-08-25T09:00:14-04:00

SEC
15-12G Form - Securities registration termination [Section 12(g)] - IGM Biosciences, Inc. (0001496323) (Filer)

2025-07-31T16:05:28-04:00

SEC
10-Q Form - Quarterly report [Sections 13 or 15(d)] - IGM Biosciences, Inc. (0001496323) (Filer)

2025-07-25T19:06:03-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - IGM Biosciences, Inc. (0001496323) (Issuer)

2025-07-25T19:03:14-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - IGM Biosciences, Inc. (0001496323) (Issuer)

2025-07-25T19:01:59-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - IGM Biosciences, Inc. (0001496323) (Issuer)

2025-07-03T17:29:00-04:00

PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: GMS, IGMS, MRC, and GRYP

2025-07-01T18:17:00-04:00

PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GNTY, IGMS, SPTN, DNOW on Behalf of Shareholders

2025-07-01T12:58:31Z

GlobeNewswire
IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right

2025-06-20T20:24:15-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - IGM Biosciences, Inc. (0001496323) (Issuer)

2025-06-20T20:23:02-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - IGM Biosciences, Inc. (0001496323) (Issuer)

2025-06-20T20:20:38-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - IGM Biosciences, Inc. (0001496323) (Issuer)

2025-06-20T20:19:14-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - IGM Biosciences, Inc. (0001496323) (Issuer)

2025-06-11T17:07:57-04:00

SEC
8-K Form - Current report, item 3.01 - IGM Biosciences, Inc. (0001496323) (Filer)

2025-06-11T17:33:39Z

Analyst Upgrades
Truist Securities Maintains Hold on IGM Biosciences, Lowers Price Target to $1

2025-05-29T16:05:25-04:00

SEC
8-K Form - Current report, items 1.01, 1.02, and 9.01 - IGM Biosciences, Inc. (0001496323) (Filer)